RecruitingPhase 1NCT05660395
A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10)
Studying Diffuse large B-cell lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- ADC Therapeutics S.A.
- Intervention
- Loncastuximab Tesirine(drug)
- Enrollment
- 56 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2027
Study locations (14)
- The Oncology Institute of Hope & Innovation - Lynwood, Lynwood, California, United States
- Hospital Sírio-Libanês - Brasília, Brasília, Brazil
- Hospital Mãe de Deus - Centro Integrado de Oncologia, Porto Alegre, Brazil
- Hospital Sírio-Libanês - São Paulo, São Paulo, Brazil
- A Beneficência Portuguesa de São Paulo - Unidade Mirant, São Paulo, Brazil
- Hospital 9 de Julho, São Paulo, Brazil
- Albert Einstein Israelite Hospital, São Paulo, Brazil
- Kyungpook National University Chilgok Hospital, Daegu, Daegu Gwang'yeogsi, South Korea
- Dong-A University Hospital, Pusan, Gyeongsangnam-do, South Korea
- Korea University Anam Hospital, Seoul, Seongbuk District, South Korea
- Seoul National University Hospital, Seoul, Seoul Teugbyeolsi [Seoul-T'ukpyolshi], South Korea
- Severance Hospital, Seoul, Seoul Teugbyeolsi, South Korea
- National Taiwan University Hospital, Taipei, Taiwan
- Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05660395 on ClinicalTrials.govOther trials for Diffuse large B-cell lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07365306Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaCity of Hope Medical Center
- RECRUITINGPHASE3NCT07493109Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOPOu Bai, MD/PHD
- RECRUITINGPHASE2NCT07493148Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCLOu Bai, MD/PHD
- RECRUITINGPHASE3NCT07409428A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCLHutchmed
- RECRUITINGPHASE2NCT07397832CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCLTianjin Medical University Cancer Institute and Hospital
- RECRUITINGPHASE3NCT07188558A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell TherapyLyell Immunopharma, Inc.
- RECRUITINGPHASE2NCT07499271Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 MutationThe First Affiliated Hospital of Soochow University
- RECRUITINGPHASE2NCT07189065A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell LymphomaGuangzhou Lupeng Pharmaceutical Company LTD.